Company: BDRX
Filing Date: 2025-06-02
Form Type: 424B3
Source: 0001214659-25-008713
Chunk: 5

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-06-02
Form: 424B3
Chunk 5
---
 chemotherapeutic
doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding systemic toxicity.

Biodexa is supported by three proprietary drug delivery technologies focused on improving
the bio-delivery and bio-distribution of medicines. Biodexa’s headquarters and R&D facility is in Cardiff, UK. For more information
visit www.biodexapharma.com.

Forward-Looking Statements
Certain statements in this announcement may constitute “forward-looking statements” within the meaning of legislation in the
United Kingdom and/or United States. Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995 and are based on management’s belief or interpretation. All statements contained in this announcement that do
not relate to matters of historical fact should be considered forward-looking statements. In certain cases, forward-looking statements
can be identified by the use of words such as “plans”, “expects” or “does not anticipate”, or “believes”,
or variations of such words and phrases or statements that certain actions, events or results “may”, “could”,
“would”, “might” or “will be taken”, “occur” or “be achieved.” Forward-looking
statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the
Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those
expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein.

Reference should be made to those documents that Biodexa shall file from time to
time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC, which contain and
identify other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking
statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking
statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above. Except as may be required
under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise any forward-looking statements
because of new information, future events or events otherwise arising.